Foresite Capital Management VI
Latest statistics and disclosures from Foresite Capital Management VI's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CGON, ALMS, CNTA, CRVS, DNLI, and represent 75.64% of Foresite Capital Management VI's stock portfolio.
- Added to shares of these 10 stocks: NERV (+$12M), CLDX (+$10M), ATAI (+$9.7M), CRNX (+$7.7M), CRVS (+$6.6M), OKUR (+$6.0M), JBIO, GHRS, DNLI, HNGE.
- Started 8 new stock positions in NERV, ATAI, ZURA, CRNX, JBIO, GHRS, OKUR, CLDX.
- Reduced shares in these 4 stocks: RAPT (-$53M), NTRA (-$15M), Atai Life Sciences Nv (-$11M), AGIO.
- Sold out of its positions in NTRA, RAPT, Atai Life Sciences Nv.
- Foresite Capital Management VI was a net seller of stock by $-8.8M.
- Foresite Capital Management VI has $460M in assets under management (AUM), dropping by 39.12%.
- Central Index Key (CIK): 0002013341
Tip: Access up to 7 years of quarterly data
Positions held by Foresite Capital Management VI consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Foresite Capital Management VI
Foresite Capital Management VI holds 17 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cg Oncology (CGON) | 32.7 | $150M | 2.2M | 67.68 |
|
|
| Alumis (ALMS) | 20.3 | $94M | 4.2M | 22.03 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 11.8 | $54M | 1.4M | 39.72 |
|
|
| Corvus Pharmaceuticals (CRVS) | 5.8 | $27M | +32% | 1.8M | 14.63 |
|
| Denali Therapeutics (DNLI) | 5.0 | $23M | +20% | 1.2M | 19.20 |
|
| Agios Pharmaceuticals (AGIO) | 3.9 | $18M | 525k | 33.83 |
|
|
| Verastem (VSTM) | 3.6 | $17M | 3.1M | 5.30 |
|
|
| Kymera Therapeutics (KYMR) | 2.6 | $12M | 146k | 83.29 |
|
|
| Minerva Neurosciences (NERV) | 2.6 | $12M | NEW | 2.0M | 6.03 |
|
| Celldex Therapeutics (CLDX) | 2.2 | $10M | NEW | 316k | 31.72 |
|
| Ataibeckley (ATAI) | 2.1 | $9.7M | NEW | 2.8M | 3.54 |
|
| Hinge Health Cl A (HNGE) | 1.8 | $8.5M | +63% | 220k | 38.56 |
|
| Crinetics Pharmaceuticals In (CRNX) | 1.7 | $7.7M | NEW | 212k | 36.32 |
|
| OnKure Therapeutics Com Cl A (OKUR) | 1.3 | $6.0M | NEW | 1.4M | 4.14 |
|
| Jade Biosciences (JBIO) | 1.0 | $4.5M | NEW | 320k | 14.05 |
|
| GH Research Ord (GHRS) | 1.0 | $4.4M | NEW | 316k | 14.06 |
|
| Zura Bio Cl A (ZURA) | 0.6 | $2.7M | NEW | 450k | 5.95 |
|
Past Filings by Foresite Capital Management VI
SEC 13F filings are viewable for Foresite Capital Management VI going back to 2025
- Foresite Capital Management VI 2026 Q1 filed May 15, 2026
- Foresite Capital Management VI 2025 Q4 filed Feb. 17, 2026
- Foresite Capital Management VI 2025 Q3 filed Nov. 14, 2025
- Foresite Capital Management VI 2025 Q2 filed Aug. 12, 2025